Catalog No.:AA000IVY

1195768-06-9 | Dabrafenib mesylate

Name: Name:Dabrafenib mesylate
Brand: AABLOCKS
SKU: AA000IVY
Availability: InStock
Rating: 90 (10 reviews)

Pack Size

Purity

Availability

Price(USD)

Quantity

10mg

99%

in stock

$6.00 $4.00

- +

25mg

99%

in stock

$12.00 $8.00

- +

50mg

99%

in stock

$21.00 $15.00

- +

100mg

99%

in stock

$39.00 $28.00

- +

98%

in stock

$1,607.00 $1,125.00

- +

Technical Information
Properties
Upstream Synthesis Route
Downstream Synthesis Route
Literature
Request for Quotation
Download SDS

Technical Information
Properties
Upstream Synthesis Route
Downstream Synthesis Route
Literature

Technical Information

Catalog Number:

AA000IVY

Chemical Name:

Dabrafenib mesylate

CAS Number:

1195768-06-9

Molecular Formula:

C24H24F3N5O5S3

Molecular Weight:

615.6681

MDL Number:

MFCD20922872

SMILES:

CS(=O)(=O)O.Nc1nccc(n1)c1sc(nc1c1cccc(c1F)NS(=O)(=O)c1c(F)cccc1F)C(C)(C)C

Properties

Computed Properties

Complexity:

910

Covalently-Bonded Unit Count:

Heavy Atom Count:

Hydrogen Bond Acceptor Count:

Hydrogen Bond Donor Count:

Rotatable Bond Count:

Upstream Synthesis Route

75-75-2

1195765-45-7

1195768-06-9

[1]Patent:US2016/46615,2016,A1,.Locationinpatent:Paragraph0113;0114;0115;0116

[2]Patent:WO2011/47238,2011,A1,.Locationinpatent:Page/Pagecolumn20-21

[3]Patent:WO2014/195852,2014,A1,.Locationinpatent:Page/Pagecolumn31;32

[4]Patent:WO2015/87279,2015,A1,.Locationinpatent:Page/Pagecolumn25;26

[5]Patent:WO2017/37587,2017,A1,.Locationinpatent:Page/Pagecolumn35

60230-36-6

1195768-06-9

[1]Patent:WO2011/47238,2011,A1,

[2]Patent:WO2014/195852,2014,A1,

[3]Patent:WO2015/87279,2015,A1,

[4]Patent:WO2017/37587,2017,A1,

1195768-20-7

1195768-06-9

[1]Patent:WO2011/47238,2011,A1,

[2]Patent:WO2014/195852,2014,A1,

[3]Patent:WO2015/87279,2015,A1,

[4]Patent:WO2017/37587,2017,A1,

1195768-18-3

1195768-06-9

[1]Patent:WO2011/47238,2011,A1,

[2]Patent:WO2014/195852,2014,A1,

[3]Patent:WO2015/87279,2015,A1,

[4]Patent:WO2017/37587,2017,A1,

1195768-19-4

1195768-06-9

[1]Patent:WO2011/47238,2011,A1,

[2]Patent:WO2014/195852,2014,A1,

[3]Patent:WO2015/87279,2015,A1,

[4]Patent:WO2017/37587,2017,A1,

Downstream Synthesis Route

75-75-2

1195765-45-7

1195768-06-9

[1]Patent:US2016/46615,2016,A1.Locationinpatent:Paragraph0113;0114;0115;0116

[2]Patent:WO2011/47238,2011,A1.Locationinpatent:Page/Pagecolumn20-21

[3]Patent:WO2014/195852,2014,A1.Locationinpatent:Page/Pagecolumn31;32

[4]Patent:WO2015/87279,2015,A1.Locationinpatent:Page/Pagecolumn25;26

[5]Patent:WO2017/37587,2017,A1.Locationinpatent:Page/Pagecolumn35

[6]Patent:WO2017/37573,2017,A1.Locationinpatent:Page/Pagecolumn32-33

60230-36-6

1195768-06-9

[1]Patent:WO2011/47238,2011,A1

[2]Patent:WO2014/195852,2014,A1

[3]Patent:WO2015/87279,2015,A1

[4]Patent:WO2017/37587,2017,A1

[5]Patent:WO2017/37573,2017,A1

1195768-20-7

1195768-06-9

[1]CurrentPatentAssignee:NOVARTISAG;Novartis(w/oSandoz)-WO2011/47238,2011,A1

[2]CurrentPatentAssignee:Novartis(w/oSandoz);NOVARTISAG-WO2014/195852,2014,A1

[3]CurrentPatentAssignee:Novartis(w/oSandoz);NOVARTISAG-WO2015/87279,2015,A1

[4]CurrentPatentAssignee:Novartis(w/oSandoz);NOVARTISAG-WO2017/37587,2017,A1

[5]CurrentPatentAssignee:NOVARTISAG;Novartis(w/oSandoz)-WO2017/37573,2017,A1

1195768-18-3

1195768-06-9

[1]Patent:WO2011/47238,2011,A1

[2]Patent:WO2014/195852,2014,A1

[3]Patent:WO2015/87279,2015,A1

[4]Patent:WO2017/37587,2017,A1

[5]Patent:WO2017/37573,2017,A1

1195768-19-4

1195768-06-9

[1]Patent:WO2011/47238,2011,A1

[2]Patent:WO2014/195852,2014,A1

[3]Patent:WO2015/87279,2015,A1

[4]Patent:WO2017/37587,2017,A1

[5]Patent:WO2017/37573,2017,A1

Literature

Title: Greger JG, et al. Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations. Mol Cancer Ther, 2012, 11(4), 909-920.

Title: Lee S, et al. Anti-inflammatory effects of dabrafenib on polyphosphate-mediated vascular disruption. Chem Biol Interact. 2016 Jul 22.

Title: Jung B, et al. Anti-septic effects of dabrafenib on HMGB1-mediated inflammatory responses. BMB Rep. 2016 Apr;49(4):214-9.

Title: Alexander M Menzies, et al. Dabrafenib and its potential for the treatment of metastatic melanoma. Drug Des Devel Ther. 2012; 6: 391–405.

Title: Posobiec LM, et al. Early Vaginal Opening in Juvenile Female Rats Given BRAF-Inhibitor Dabrafenib Is Not Associated with Early Physiologic Sexual Maturation. Birth Defects Res B Dev Reprod Toxicol. 2015 Dec;104(6):244-52.

Quotation Request

Company Name:

Contact Person:

Email:

Quantity Required:

Country:

Additional Info:

SDS